Hypothermic Kidney Machine Perfusion With Omnisol
NCT07920926, Not applicable, Not yet recruiting, Vivalyx GmbH
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Hypothermic Kidney Machine Perfusion With Omnisol | ClinicalTrials.gov |
| NCT number | NCT07920926 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 16 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Vivalyx GmbH | ClinicalTrials.gov |
| Conditions | End Stage Renal Disease (ESRD), Kidney Transplant, Kidney Failure, Renal and Urinary Tract Therapeutic Procedures | ClinicalTrials.gov |
| Interventions | Omnisol organ preservation solution | ClinicalTrials.gov |
| First posted | 2026-11-06 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Incidence of Delayed Graft Function | 7 days post-transplantation. | Incidence of delayed graft function, defined as the requirement for at least one dialysis session within the first 7 days after transplantation, excluding a single dialysis session performed solely for hyperkalemia or volume overload. | ClinicalTrials.gov |
| Primary | Graft Survival | 30 days post-transplantation. | 30-day graft survival, censored and uncensored for recipient death. | ClinicalTrials.gov |
| Secondary | Graft Survival | 3, 6 and 12 months post-transplantation. | Graft survival, censored and uncensored for recipient death. | ClinicalTrials.gov |
| Secondary | Recipient Survival | 30 days, 3, 6 and 12 months post-transplantation. | Rate of recipient survival. | ClinicalTrials.gov |
| Secondary | Kidney Graft Function | 30 days, 3, 6 and 12 months post-transplantation. | Estimated glomerular filtration rate (eGFR) calculated using the CKD-EPI creatinine equation. | ClinicalTrials.gov |
| Secondary | Primary Non-Function | 30 days, 3, 6 and 12 months post-transplantation. | Incidence of irreversible graft failure with no initial evidence of graft function following transplantation. | ClinicalTrials.gov |
| Secondary | Duration of Delayed Graft Function | 30 days post-transplantation. | Duration of delayed graft function in participants who require renal replacement therapy after kidney transplantation. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)